“Live healthier longer” – Publication of a book on the medicine and science of longevity Biophytis announces the publication of a book written by Stanislas Veillet, CEO and co- founder of the company, together with René Lafont, Professor Emeritus at Sorbonne University and co- founder of Biophytis, and Jean Mariani, Professor and Director of the…
Biophytis announces the publication of the results of its COVA phase 2-3 study in eClinicalMedicine, part of The Lancet Biophytis announces the publication of an article on the results of its COVA phase 2-3 clinical trial in the treatment of respiratory symptoms in severe forms of COVID-19 in eClinicalMedicine, a medical journal part of the…
Biophytis announces the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract Biophytis announces the drawing of a new tranche of Bonds Redeemable in Cash and New and Existing Shares (ORNANE) under its existing convertible bond agreement with Atlas, a specialized investment fund based in New York (United States). Fullscreen Mode
Biophytis announces its participation in several conferences in Europe and the US during the first quarter of 2024 Biophytis management will be in San Francisco for meetings with potential partners and investors at the 42nd JP Morgan Healthcare Conference, to be held from 8 to 11 January 2024. In addition, the company will be present:…
Biophytis and the University of Liège explore the potential of Sarconeos (BIO101) in the treatment of viral respiratory failure Biophytis announces the signing of a new partnership with the University of Liège to carry out a range of preclinical research projects, particularly in the treatment of respiratory failure caused by the flu virus Influenza. Under…
Biophytis appoints Yann Meunier and Bernard Lévy to its Scientific Advisory Board Biophytis announced the appointment of Dr Yann Meunier and Professor Bernard Lévy to its Scientific Advisory Board. Yann Meunier is a US-based healthcare professional, currently Professor and Director of the International Institute of Medicine and Science, Inc (IIMS), where he leads the development…
Biophytis announces the success of its capital increase with preferential subscription rights for approximately €1.96 million Biophytis announces the successful completion of its capital increase with shareholders’ pre-emptive subscription rights (DPS) through the issue of shares with redeemable share warrants (ABSAR), for an amount, including issue premium, of approximately €1.96 million (the “Capital Increase”). Stanislas…
Biophytis to attend BIO-Europe in Munich Biophytis announces that the company is attending the BIO-Europe conference which will be held in Munich, Germany, November 6th to 8th 2023. The conference will, as every year, bring together all the players in the pharmaceutical and biotech industries. As part of the international development strategy for Sarconeos (BIO101)…
In an exclusive interview with Biotech Info (in French), Stanislas Veillet, CEO & co-founder of Biophytis, unveils the capital increase for Sarconeos (BIO101) targeting severe COVID-19 & sarcopenia. With Phase 3 trials in sight, shareholders are invited to join this pivotal phase. Read here